Pseudoxanthoma elasticum (PXE) is a rare inherited condition in which calcium deposits gradually build up in the elastic fibers of the skin, eyes, and blood vessels, causing tissues that should be flexible to become stiff and fragile. The underlying cause is a faulty copy of the ABCC6 gene, which both parents must carry for a child to develop the disease. Because the damage accumulates over years and the earliest skin changes can look like ordinary aging, PXE is frequently misdiagnosed or caught late. Research into treatments that slow the calcification process has accelerated in the past decade, and several promising approaches are now in or near clinical trials.
How the ABCC6 Gene Causes Calcification
PXE is classified as autosomal recessive, meaning a person needs two defective copies of the ABCC6 gene to develop the disease. People who carry just one faulty copy are generally unaffected, though they can pass the gene to their children.1Genetics in Medicine. Pseudoxanthoma elasticum: Wide phenotypic variation in homozygotes and no signs in heterozygotes for the c.3775delT mutation in ABCC6 The ABCC6 protein is produced mainly in the liver and kidneys, not in the tissues it ultimately protects. Its job is to push ATP out of cells, where enzymes quickly convert that ATP into inorganic pyrophosphate (PPi). Pyrophosphate acts as a natural brake on calcification throughout the body. When ABCC6 does not work properly, PPi levels in the blood and tissues drop, and calcium and phosphate begin to crystallize in places where they should not.2PubMed Central. Dietary Pyrophosphate Modulates Calcification in a Mouse Model of Pseudoxanthoma Elasticum: Implication for Treatment of Patients
The tissues hit hardest are those with a high density of elastic fibers: the skin (especially on the neck and in body folds), the membrane at the back of the eye known as Bruch’s membrane, and the walls of small-to-medium arteries. Over time, these elastic fibers become brittle, fragment, and accumulate mineral deposits. The result is a progressive loss of elasticity in skin, a growing risk of vision loss, and premature hardening of arteries that can restrict blood flow to the legs and other organs.3PubMed Central. ABCC6 and Pseudoxanthoma Elasticum: The Face of a Rare Disease from Genetics to Advocacy
What PXE Looks Like on the Skin
The earliest visible sign of PXE is usually a crop of small, yellowish or skin-colored bumps on the sides and back of the neck. These papules tend to cluster together and, over time, the surrounding skin becomes loose and develops a “plucked chicken” texture with fine wrinkles. The same changes can appear in the armpits, inner elbows, groin, behind the knees, and around the belly button.4PubMed Central. Pseudoxanthoma elasticum, a difficult diagnostic in patient with dark skin If a skin biopsy is taken, it shows calcium deposits in the middle layer of the dermis and clumped, fragmented elastic fibers, a pattern distinctive enough to confirm a diagnosis.5PubMed. Pseudoxanthoma elasticum with cerebrovascular accident
These skin changes typically appear in the teenage years or early adulthood, though they are sometimes overlooked because they can look like premature aging or other skin conditions. Diagnosis is especially tricky on darker skin, where the yellowish color of the papules is much less obvious. In those cases, the looseness and wrinkling of skin in characteristic locations may be the clue that leads a dermatologist to suspect PXE.6PubMed Central. Pseudoxanthoma elasticum, a difficult diagnostic in patient with dark skin While the skin findings are cosmetically bothersome, they are not dangerous in themselves. The real medical concern with PXE lies in the eyes and the vascular system.
Eye Involvement and Vision Loss
The eye changes in PXE center on structures called angioid streaks: irregular, grayish lines that radiate outward from the optic disc at the back of the eye. They result from cracks in the calcified Bruch’s membrane, the thin layer that supports the retina’s blood supply.7PubMed Central. Angioid Streaks in Pseudoxanthoma Elasticum Roughly half of all angioid streak cases are linked to PXE.8PubMed. ABCC6 gene mutational spectrum and ocular features in Mexican patients with pseudoxanthoma elasticum-related angioid streaks On their own, the streaks may not affect sight. The danger comes when the cracks allow abnormal blood vessels to grow underneath the retina, a complication called choroidal neovascularization (CNV). These fragile new vessels can leak fluid or blood into the macula, leading to rapid, significant vision loss.
A large study of about 300 patients found that CNV was present in roughly half of them, and retinal atrophy in about a quarter. The wider the angioid streaks, the greater the likelihood of both CNV and macular degeneration, even after adjusting for age.9PubMed. The Extent of Angioid Streaks Correlates With Macular Degeneration in Pseudoxanthoma Elasticum This is why regular eye exams are strongly recommended for anyone with PXE. Catching CNV early opens a window for treatment that can preserve useful vision.
The standard treatment for CNV in PXE is the same class of drugs used for wet age-related macular degeneration: anti-VEGF injections delivered directly into the eye. In a long-term follow-up of patients treated this way, visual acuity improved or stabilized in all treated eyes, and measurements of retinal swelling dropped significantly.10Retina. Long-Term Outcomes of Intravitreal Antivascular Endothelial Growth Factor Therapy for the Management of Choroidal Neovascularization in Pseudoxanthoma Elasticum Anti-VEGF therapy does not fix the underlying calcification problem, but it can stop or slow the vision loss that is often the most devastating consequence of the disease.
Cardiovascular Complications
The same mineralization process that stiffens elastic fibers in the skin and eyes also hardens the walls of small and medium-sized arteries. For people with PXE, this translates into an unusually high rate of peripheral artery disease (PAD), a condition in which narrowed arteries reduce blood flow, especially to the legs. In a cohort of 285 PXE patients with a median age of 58, just over half met the criteria for PAD.11European Journal of Vascular and Endovascular Surgery. Peripheral Artery Disease and Lower Limb Interventions in Patients with Pseudoxanthoma Elasticum The most common symptom is intermittent claudication, a cramping pain in the legs during walking that eases with rest.12PubMed Central. Pseudoxanthoma elasticum
Some patients require procedures to reopen blocked arteries, but the reintervention rate is high. In the same study, more than a third of all recorded vascular procedures were repeat revascularizations in patients who had already been treated, often within a year of the initial intervention and frequently because the artery had occluded again.13European Journal of Vascular and Endovascular Surgery. Peripheral Artery Disease and Lower Limb Interventions in Patients with Pseudoxanthoma Elasticum This high failure rate likely reflects the ongoing calcification process, which makes the arteries of PXE patients a particularly hostile environment for standard interventions. Cardiovascular screening and management of traditional risk factors like high blood pressure and cholesterol are considered essential in PXE care, even for younger patients.
Why Severity Varies So Much Between Patients
One of the most puzzling aspects of PXE is how differently it can affect people who carry the same ABCC6 mutations. Two siblings with identical genetic errors in ABCC6 may end up with dramatically different symptoms: one might develop severe vision loss in their thirties while the other has only mild skin changes decades later.14PubMed Central. Rare Modifier Variants Alter the Severity of Cardiovascular Disease in Pseudoxanthoma Elasticum Researchers have found no strong link between the specific ABCC6 mutation a person carries and the severity of their disease.
The leading explanation is that other genes act as “modifiers,” dialing the severity of calcification up or down in different tissues. Studies in mice bred to carry the same ABCC6 defect but from different genetic backgrounds show wildly different levels of mineralization, confirming that other parts of the genome matter.15PubMed Central. Quantitative Trait Locus and Integrative Genomics Revealed Candidate Modifier Genes for Ectopic Mineralization in Mouse Models of Pseudoxanthoma Elasticum Additional enzymes involved in pyrophosphate regulation, along with environmental factors like diet and lifestyle, likely contribute to the variability as well.16PubMed Central. Rare Modifier Variants Alter the Severity of Cardiovascular Disease in Pseudoxanthoma Elasticum For patients and their families, the practical takeaway is that a genetic diagnosis of PXE does not reliably predict how the disease will progress. Regular monitoring of eyes, skin, and cardiovascular health remains the best strategy regardless of mutation type.
Look-Alike Conditions and Diagnostic Challenges
PXE is not the only condition that causes loose, wrinkled skin with elastic fiber changes. A related group of disorders can produce overlapping features that confuse the clinical picture. Mutations in the GGCX gene, for instance, can cause a phenotype that blends features of PXE with cutis laxa, another connective-tissue disorder. GGCX encodes an enzyme involved in activating vitamin K-dependent proteins, and patients with these mutations sometimes also have clotting abnormalities, a feature not seen in classic PXE.17PubMed Central. GGCX mutations in a patient with overlapping pseudoxanthoma elasticum/cutis laxa-like phenotype Similarly, mutations in ENPP1, another gene involved in pyrophosphate metabolism, can produce either PXE or a more severe infantile calcification disorder depending on the individual.18PubMed Central. Rare Modifier Variants Alter the Severity of Cardiovascular Disease in Pseudoxanthoma Elasticum
Because of this overlap, genetic testing has become an increasingly important part of confirming a PXE diagnosis. A skin biopsy showing the classic calcium deposits and fragmented elastic fibers gets clinicians most of the way there, but molecular confirmation through ABCC6 sequencing pins down the exact condition and rules out mimics. This distinction matters for counseling about inheritance risk and for guiding decisions about screening for complications that differ between PXE and its look-alikes.
Emerging Treatments Targeting Calcification
Because PXE stems from a shortage of pyrophosphate, researchers have been exploring ways to restore anti-calcification defenses. The most advanced approach involves etidronate, a bisphosphonate drug that mimics pyrophosphate’s ability to inhibit mineral crystal formation. In a randomized trial, patients receiving etidronate showed a decrease in arterial calcification of about 4% on average, while the placebo group saw an increase of about 8%. The etidronate group also experienced far fewer episodes of new abnormal blood vessel growth in the eye.19PubMed. Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum A separate analysis of the same trial confirmed that etidronate halted calcification progression in most arterial beds.20PubMed. Etidronate halts systemic arterial calcification in pseudoxanthoma elasticum
Longer-term follow-up data are now available as well. A six-year observational study found that the rate of calcification progression roughly halved while patients were on cyclical etidronate compared to periods without the drug.21PubMed Central. Cyclical Etidronate Reduces the Progression of Arterial Calcifications in Patients with Pseudoxanthoma Elasticum: A 6-Year Prospective Observational Study These results are encouraging, but mouse studies have shown that etidronate can prevent new mineralization without reversing deposits that have already formed, which suggests that early treatment may be key.22PubMed Central. Etidronate prevents, but does not reverse, ectopic mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6-/-)
A second strategy goes even more directly at the root problem: giving patients pyrophosphate itself by mouth. Early work demonstrated that oral pyrophosphate can be absorbed in humans and that it inhibits calcification in PXE mouse models. Researchers have tested several formulations, including sodium-free versions that avoid the cardiovascular concerns of high sodium intake, and have identified compounds with improved absorption.23PubMed Central. Oral supplementation of inorganic pyrophosphate in pseudoxanthoma elasticum Clinical trials in humans have not yet begun, but this approach could eventually complement or replace bisphosphonate therapy if the bioavailability hurdle can be solved at scale.
A third line of investigation involves dietary modifications tested in mouse models. Increasing dietary magnesium significantly reduced connective tissue mineralization in mice that lack ABCC6, pointing toward a potential low-risk adjunctive measure.24PubMed Central. Elevated dietary magnesium prevents connective tissue mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6(-/-)) It is worth noting that mouse results do not always translate to humans, and no controlled trials of magnesium supplementation in PXE patients have been reported. Still, the finding fits with the broader understanding that mineral balance influences calcification and has prompted interest in exploring dietary interventions alongside pharmaceutical ones.
Pregnancy and PXE
For women with PXE who are considering pregnancy, there has historically been concern about whether the physical demands of pregnancy could worsen cardiovascular or eye complications. A comprehensive review of the available evidence concluded that pregnant women with PXE do not face a meaningfully higher risk of obstetric complications compared to women without the condition.25PubMed Central. Comprehensive Literature Review of Obstetric Outcomes and Fetal Risk during Pregnancy with Pseudoxanthoma Elasticum An earlier study found that while a small number of pregnancies were associated with worsening skin changes, there was no correlation between having been pregnant and the ultimate severity of skin, eye, or cardiovascular disease. Rates of gastrointestinal bleeding during pregnancy, once thought to be high, turned out to be much lower than older case reports suggested, and retinal complications during pregnancy were uncommon.26PubMed. Pregnancy and obstetrical outcomes in pseudoxanthoma elasticum
The current consensus is that there is no medical basis for advising women with PXE to avoid pregnancy. That said, monitoring cardiac, vascular, and retinal health during pregnancy is sensible, just as it would be outside of pregnancy. And because PXE is autosomal recessive, the child of an affected woman will be a carrier at minimum, but will only develop PXE if the other parent also carries a defective ABCC6 copy. Genetic counseling before or during pregnancy can clarify these risks for individual families.
Living with PXE and Quality of Life
The psychological burden of PXE is shaped less by the skin changes, which are medically benign, and more by vision impairment and the anxiety of cardiovascular disease. Research examining quality of life in PXE patients found that vision loss was a strong predictor of reduced emotional well-being and vision-specific daily functioning, regardless of whether cardiovascular complications were also present.27PubMed Central. The relative impact of vision impairment and cardiovascular disease on quality of life: the example of pseudoxanthoma elasticum General physical health scores, interestingly, were less affected, which may reflect the fact that PXE is a slowly progressive condition that people adapt to over time.28Investigative Ophthalmology & Visual Science. The Impact Of Concurrent Vision Loss And Systemic Cardiovascular Disease On Health-related Quality Of Life In Pseudoxanthoma Elasticum
Patient advocacy organizations have played an unusually active role in PXE research. PXE International, founded by parents of affected children, helped establish an international patient registry and biobank that has fueled much of the genetic and clinical research described above.29PubMed. Genetic Alliance Registry and BioBank: a novel disease advocacy-driven research solution For a disease that affects a small number of people worldwide, this kind of organized patient participation has been critical in attracting research funding, recruiting trial participants, and pushing the science forward. People newly diagnosed with PXE often find that connecting with these networks provides not just emotional support but also access to the latest information about clinical trials and management strategies.
Dietary and Lifestyle Factors Under Investigation
Beyond pharmaceutical interventions, there is growing interest in whether dietary factors influence the course of PXE. The mouse studies on dietary magnesium and phosphate showed that mineral balance can tip the scales toward or away from calcification in genetically susceptible animals.30PubMed Central. Elevated dietary magnesium prevents connective tissue mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6(-/-)) Some PXE patients have adopted higher-magnesium diets or supplements on their own, though formal clinical guidance on this remains limited due to the absence of controlled human trials. Similarly, work on dietary pyrophosphate supplementation in mouse models showed that oral pyrophosphate could reduce calcification, raising the question of whether pyrophosphate-rich foods or supplements might eventually play a role.31PubMed Central. Dietary Pyrophosphate Modulates Calcification in a Mouse Model of Pseudoxanthoma Elasticum: Implication for Treatment of Patients
Lifestyle factors like exercise come with their own considerations. Cardiovascular fitness is generally beneficial and may help manage peripheral artery disease symptoms, but vigorous activities that sharply raise blood pressure could theoretically stress already calcified vessels. Eye trauma, even minor impacts, poses a greater risk when Bruch’s membrane is already compromised by angioid streaks, so contact sports are often discouraged in clinical practice. The evidence base for specific lifestyle recommendations is thin, and most guidance comes from clinical experience rather than controlled studies. What is clear is that the standard cardiovascular risk factors, including smoking, uncontrolled blood pressure, and high cholesterol, are especially worth managing aggressively in someone whose arteries are already predisposed to stiffening.